Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18984Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Agorastos, T. | en |
| dc.contributor.author | Vaitsi, V. | en |
| dc.contributor.author | Paschopoulos, M. | en |
| dc.contributor.author | Vakiani, A. | en |
| dc.contributor.author | Zournatzi-Koiou, V. | en |
| dc.contributor.author | Saravelos, H. | en |
| dc.contributor.author | Kostopoulou, E. | en |
| dc.contributor.author | Constantinidis, T. | en |
| dc.contributor.author | Dinas, K. | en |
| dc.contributor.author | Vavilis, D. | en |
| dc.contributor.author | Lolis, D. | en |
| dc.contributor.author | Bontis, J. | en |
| dc.date.accessioned | 2015-11-24T18:56:06Z | - |
| dc.date.available | 2015-11-24T18:56:06Z | - |
| dc.identifier.issn | 0378-5122 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18984 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Endometrial Hyperplasia/*drug therapy/pathology | en |
| dc.subject | Estrogen Receptor Modulators/*administration & dosage | en |
| dc.subject | Female | en |
| dc.subject | Gonadotropin-Releasing Hormone/*agonists | en |
| dc.subject | Humans | en |
| dc.subject | Injections | en |
| dc.subject | Leuprolide/*administration & dosage | en |
| dc.subject | Middle Aged | en |
| dc.subject | Norpregnenes/*administration & dosage | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1016/j.maturitas.2003.08.008 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/15172086 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S037851220300313X/1-s2.0-S037851220300313X-main.pdf?_tid=7740037473559da7cf450b5735c5e8a1&acdnat=1333540571_facf7cfd63c3458555279c9928516d0c | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2004 | - |
| heal.abstract | OBJECTIVES: To investigate the response of the various hyperplastic disorders of the endometrium to a prolonged treatment with leuprolide acetate, a gonadotropin-releasing hormone agonist (GnRH-a), plus tibolone, as add-back therapy, and further to study if the tibolone addition reduces the hypoestrogenic actions of the GnRH-analogue. METHODS: We treated 26 women with histologically confirmed simple (n = 9), complex (n = 15) or atypical (n = 2) endometrial hyperplasia (EH) for 12 months with monthly injections of 1Ampulle/3.75 mg of leuprolide acetate, followed by tibolone, 2.5mg per day per os. Every woman underwent a hysteroscopic evaluation and biopsy of the endometrium after 3 (in cases with atypical EH), 6 and 12 months of treatment, as well as after 12 and 24 months of follow-up. The clinical, paraclinical and laboratory course of the disease was followed-up by using of a climacteric scoring system and by testing of various parameters. RESULTS: The histopathologic evaluation of the endometria revealed regression of EH in all women after 12 months of treatment, however, during the first 2 years of follow-up EH reappeared in four women (4/21, 19%). Bone mineral density and serum parameters did not show significant changes during treatment, whereas only a mild suffering from hypoestrogenic side-effects was noted. CONCLUSIONS: It seems that the combined GnRH-a/tibolone treatment in women with EH is a potent alternative, so far as the endometrial status and the clinical course of the disease are concerned, whereas tibolone appears to act sufficiently as add-back therapy to prolonged GnRH-a treatment. The probability of relapse of the disease during the follow-up period makes the close monitoring of the endometrium after cessation of the treatment absolutely necessary. | en |
| heal.journalName | Maturitas | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Agorastos-2004-Prolonged use of gon.pdf | 75.95 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
